George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
See update
Company were totally surprised with the data and are reviewing it
Any theories of why no large forward selling before last rns.....seems odd...news nearly always leaks to insiders
I cam see 4p
That will be 3p soon
Can sell 400,000 at 2.25p
Whatever we say it is still oversold it’s worth a lot more than it stands at present.
As at 31 July 2023, Ovoca has an unaudited cash balance of €2.6 million, lets see what they decide to do with that cash pile
"great potential" ...a few days after their trial was a complete failure !
I still hold but keep it real, I think the cash shell route would be the best outcome now
This is a share that has great potential this has to be worth at least 4/5p this is way way oversold and will move up nicely this week.
Laura your posts come across as desperation, a trader who does not want to hold for too long and they are not working. Be patient and see what happens otherwise sell and move to your next day trade.
This has potential to be 4/5p well oversold.
Bargain price to be had here.
Moves soon I think
We are surprised and disappointed that the Study did not have a positive conclusion regarding the superiority of Orenetide versus placebo. The Company now intends to analyse the results from the Study in further detail, including investigating the reasons for potential differences between the Study results and results from previously conducted clinical trials of Orenetide
Thanks
Perhaps add to your 112 posts on AVCT rather then clog up here
Particularly as the major shareholders are Russian. Oh dear. You couldn't make it up Laura, or should I say Laura Golovanovska.🤣🤣🤣
No reason at all but, completely unrelated, you are flogging an obviously dead horse so good luck with that!
Any resson why we're talking about avct ?
Avacta is too big for me I like small caps, I used to have them as low as 13p then they got in on the pharma covid bubble and went nuts.
Ovb does have big shareholders so again at 2p for me it's not worth selling, they might just do something else, plenty of tax losses etc etc so going to hold until hopefully a spike comes along then I will move on
...So Avacta buy two profitable fully trading, going concern businesses with part of the bond money and you don't include any revenues from that or milestone paymenst from major partnerships. LG Chem is taking their product into clinic next year plus Point partnership. You assume no revenue and no partnerships for Pre|cision - just outgoing funcds.
I think you don't really know what you're talking about. AVA6k is a modified existing drug and using models for CoS for drug trials don't really apply...but you alrwady knew that didn't you?...or not?
Uninformed, but willing to spread the word....numpty comes to mind
This could really move quickly as the BOD own 50% and other shares holders own 40%, will be interesting to see what happens next week or so
https://ovocabio.com/major-shareholders/https://ovocabio.com/major-shareholders/
Just some facts.
Avacta is the company, AVA6000 is the lead product. Loan repayments are quarterly, not monthly. Trial news due soon - good news or even better news. Many ways to raise further cash (all small biopharma companies need constant top-ups unti there is a revenue stream - it's normal!). Those % figures - just meaningless supposition.
Avacta might end up being be a wonderful product but….
£300m mcap, £44M CLN, £40m cash last December so maybe what ~£20-25m cash currently?, monthly issuing of stock to pay bond interest
By default over time It’s going to get hammered in to the ground, might be great for bondholders who pick up cheap equity but the odds are less favourable for holders of existing equity, I’d say 85% chance of a 75%-90% drop there in a year or two when cash runs out and bonds outstanding, 10% chance sp ranges with a downward trend, 5% chance it rises and you get the moon shot RNS but even then for only 3x potential it’s currently priced on the high side, I’d was 5-10x potential.
I know it has its fan clubs but My gut says it inevitably runs out of money and equity screwed, but I do hope it does end favourably, or atleast a product they are involved in comes to market and actually helps people.
As for OVB - just test it again elsewhere, if it works great, it not move on.
Doesnt make me wrong about avacta tho beanevisat
Chance of success is way above 50% for this to become a multi billion pound company
thats a fact.
Crap here but if people are desisive and act fast they can recover all losses and more at avacta
another fact
It's never nice when you see your money wiped out with your investment so those who have lost out here have my sympathy.
I'd never heard of Ovoca Bio unti I saw yesterday's disastrous RNS. Immediately I knew I'd never ever have invested in this company, and for these reasons:
1. There is only one drug candidate in the pipeline, so the company is a binary play: win big or lose everything.
2. The trials by Ivix were done in Russia. I would never trust anything coming out of Russia. They have a culture of lying: of lying openly, blatantly and straight-facedly. It's called 'vranyo' and it is done for personal progression.
3. Ovoca Bio is based in Ireland and I would never trust an Irish company. Their flavour of lying is called 'blarney'.
I see some are claiming that they've bought more OVB shares at this knockdown price as the SP will be going up again. Don't believe them. (Have they bought or are they trying to get others to buy and thereby raise the price so that they can sell their holding at a better price?) In any case, this company is a dog and is dead in the water. There may be assets in the form of a cash pile but that will dwindle away into the directors' pockets. This company has no product and no future.
Basically you want them to write off the whole drug and become a cash shell then there is hope